Anne Marinier is the Chief Chemist at ExCellThera. She is also Principal Investigator and Director of Medicinal Chemistry at the Institute for Research in Immunology and Cancer (IRIC), and Associate Professor in the Department of Chemistry at the Université de Montréal.
She has close to 25 years of experience in medicinal chemistry and a strong industrial expertise in all aspects of drug discovery. Before joining IRIC, Dr. Marinier was Group Leader of the Drug Discovery Research group at Bristol-Myers Squibb.
She currently heads IRIC’s medicinal chemistry platform, which comprises 39 chemists and biologists. This infrastucture, of which she spearheaded the creation and implementation in 2007 with federal and provincial funding of more than $9M, supports drug discovery research programs from IRIC scientists and collaborators/pharmaceutical company partners. The group is highly proficient in SAR (structure-activity relationships) development, hit and lead optimization and has already progressed two molecules in Phase I clinical studies in collaboration with Bristol-Myers Squibb. In addition, a third compound named UM171 and used as a cord blood stem cell expansion factor has been discovered in collaboration with Dr Guy Sauvageau and his laboratory members. This international discovery is the scientific basis of ExCellThera.
Medicinal chemists in her group have also developed an extensive expertise in chemical probes design and synthesis for identification of novel biological targets, as these play a key role in building innovative therapeutic approaches for the treatment of cancer.
Anne Marinier obtained her Ph.D. in organic synthesis at the Université de Sherbrooke and pursued post-doctoral studies at the Washington University School of Medicine in St. Louis.